236 related articles for article (PubMed ID: 30833418)
1. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM; Brown Swigart L; Ahmed Z; Sayaman RW; Renner D; Kalashnikova E; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Asare S; Liu MC; Albain K; Chien AJ; Forero-Torres A; Isaacs C; Nanda R; Tripathy D; Rodriguez A; Sethi H; Aleshin A; Rabinowitz M; Perlmutter J; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Cancer Cell; 2023 Jun; 41(6):1091-1102.e4. PubMed ID: 37146605
[TBL] [Abstract][Full Text] [Related]
6. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract][Full Text] [Related]
7. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
[TBL] [Abstract][Full Text] [Related]
8. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
Lindskrog SV; Birkenkamp-Demtröder K; Nordentoft I; Laliotis G; Lamy P; Christensen E; Renner D; Andreasen TG; Lange N; Sharma S; ElNaggar AC; Liu MC; Sethi H; Aleshin A; Agerbæk M; Jensen JB; Dyrskjøt L
Clin Cancer Res; 2023 Dec; 29(23):4797-4807. PubMed ID: 37782315
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
[TBL] [Abstract][Full Text] [Related]
12. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
13. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
[TBL] [Abstract][Full Text] [Related]
15. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
16. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.
McDonald BR; Contente-Cuomo T; Sammut SJ; Odenheimer-Bergman A; Ernst B; Perdigones N; Chin SF; Farooq M; Mejia R; Cronin PA; Anderson KS; Kosiorek HE; Northfelt DW; McCullough AE; Patel BK; Weitzel JN; Slavin TP; Caldas C; Pockaj BA; Murtaza M
Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391323
[TBL] [Abstract][Full Text] [Related]
17. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
18. Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ciriaco N; Zamora E; Escrivá-de-Romaní S; Miranda Gómez I; Jiménez Flores J; Saura C; Sloane H; Starus A; Fredebohm J; Georgieva L; Speight G; Jones F; Ramón Y Cajal S; Espinosa-Bravo M; Peg V
Ther Adv Med Oncol; 2022; 14():17588359221139601. PubMed ID: 36479470
[TBL] [Abstract][Full Text] [Related]
19. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Zhou Q; Gampenrieder SP; Frantal S; Rinnerthaler G; Singer CF; Egle D; Pfeiler G; Bartsch R; Wette V; Pichler A; Petru E; Dubsky PC; Bago-Horvath Z; Fesl C; Rudas M; Ståhlberg A; Graf R; Weber S; Dandachi N; Filipits M; Gnant M; Balic M; Heitzer E
Clin Cancer Res; 2022 Feb; 28(4):697-707. PubMed ID: 34862246
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.
Li S; Lai H; Liu J; Liu Y; Jin L; Li Y; Liu F; Gong Y; Guan Y; Yi X; Shi Q; Cai Z; Li Q; Li Y; Zhu M; Wang J; Yang Y; Wei W; Yin D; Song E; Liu Q
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
